Zimmer Biomet (NYSE:ZBH) Releases FY 2025 Earnings Guidance

Zimmer Biomet (NYSE:ZBH - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 7.900-8.100 for the period, compared to the consensus estimate of 8.210. The company issued revenue guidance of $8.1 billion-$8.3 billion, compared to the consensus revenue estimate of $7.9 billion.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research analyst reports. Royal Bank of Canada decreased their price target on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday. Wells Fargo & Company lowered their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the stock a "buy" rating in a research note on Tuesday. JMP Securities cut their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday. Finally, The Goldman Sachs Group lowered their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $114.15.

Zimmer Biomet Price Performance

NYSE:ZBH traded up $0.94 during trading hours on Thursday, hitting $95.07. The company's stock had a trading volume of 2,886,072 shares, compared to its average volume of 1,707,374. Zimmer Biomet has a 52-week low of $89.92 and a 52-week high of $122.25. The company has a market capitalization of $18.81 billion, a PE ratio of 21.36, a PEG ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The business's 50-day moving average is $104.81 and its two-hundred day moving average is $106.24.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. Zimmer Biomet's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.94 earnings per share. As a group, research analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.01%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

An institutional investor recently bought a new position in Zimmer Biomet stock. Brighton Jones LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,936 shares of the medical equipment provider's stock, valued at approximately $204,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.